

EXHIBIT C
**CLAIMS THAT WILL BE PENDING UPON ENTRY OF THE INSTANT
AMENDMENT**

FILED September 5, 2002
IN U.S. PATENT APPLICATION SERIAL NO. 09/161,122
ATTORNEY DOCKET NO. 7682-045-999

2. (amended) An isolated infectious Respiratory Syncytial Virus (RSV) particle containing an RSV RNA comprising a binding site specific for an RNA-directed RNA polymerase operatively linked to an RSV RNA comprising sequences encoding antigenic polypeptides of both RSV-A and RSV-B.

13. (amended) A vaccine comprising a chimeric Respiratory Syncytial Virus (RSV) the genome of which contains the reverse complement of an mRNA coding sequence operatively linked to a polymerase binding site of an RSV and a pharmaceutically acceptable carrier.

18. (amended) The vaccine of Claim 13 in which the mRNA coding sequence encodes G and F genes of both Respiratory Syncytial Virus A and Respiratory Syncytial Virus B.

25. (new) The isolated infectious Respiratory Syncytial Virus (RSV) particle of claim 2, wherein the RSV RNA further comprises a L gene mutation.

26. (new) The isolated infectious Respiratory Syncytial Virus (RSV) particle of claim 2, wherein the RSV RNA further comprises a deletion of M2-ORF1 and/or SH-